Position of the Transparency Council – Erwinase (crisantaspasum)
At its meeting on 24 March 2025, the Transparency Council adopted position No. 35/2025 on the evaluation of the drug Erwinase (crisantaspasum) as part of chemotherapy: C91.0 acute lymphoblastic leukemia